Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies

Reuters09-05
<a href="https://laohu8.com/S/LIXT">Lixte Biotechnology Holdings Inc.</a> Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> Synergies

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced the continuation of its clinical programs involving LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, designed to enhance cancer treatment. LB-100 is currently being evaluated in collaboration with pharmaceutical partners in various cancer studies. These include a trial for ovarian clear-cell carcinoma in partnership with GSK, which is providing Dostarlimab and supporting full trial funding. Additionally, LB-100 is being assessed for MSS colorectal cancer in collaboration with Roche at the Netherlands Cancer Institute, although this study is currently under a temporary voluntary safety pause due to early adverse events. The results of these trials have not yet been presented, as the studies are ongoing. Lixte aims to validate LB-100's safety and efficacy and explore its potential to improve the effectiveness of existing cancer therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 265118) on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment